DMRA:NASDAQ, Damora Therapeutics Inc Com (New)

DMRA stock overview

Damora Therapeutics Inc Com (New) (DMRA:NASDAQ) closed at $23.22 on November 20, 2026, down 4.44% on the day. The stock trades 39.4% below its 52-week high of $38.33 and 47.3% above its 52-week low of $15.76. Over the past year, it gained 42.4%. Damora Therapeutics Inc Com (New) is part of the Health Care sector.

Key figures

Price
$23.22
Day change
-4.44%
Volume
643,377
Average volume
576,726
Market cap
1B+
52-week range
$15.76 – $38.33
50-day average
$21.79
200-day average
$25.44

Price action over the past year

In 252 trading sessions since November 20, 2025, DMRA closed higher on 125 days (50%). Its best day was February 12, 2026 (+37.75%) and its worst was December 30, 2025 (-24.65%). The stock moved 10% or more in a single session 22 times.

Recent signals

DMRA news

About Damora Therapeutics Inc Com (New)

Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.

Similar stocks

Find more stocks like DMRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.